vs
Side-by-side financial comparison of Allegion (ALLE) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Allegion is the larger business by last-quarter revenue ($1.0B vs $708.5M, roughly 1.5× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 14.3%, a 4.8% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 9.3%). Allegion produced more free cash flow last quarter ($200.5M vs $188.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 7.5%).
Allegion plc manufactures and sells mechanical and electronic security products and solutions worldwide. The company offers door closers, controls, and exit devices; locks, locksets, portable locks, and key systems and services; electronic security products and access control systems; time, attendance, and workforce productivity systems; doors and door systems; and other accessories. The company sells its products and solutions to end-users in commercial, institutional, and residential facili...
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
ALLE vs MEDP — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $708.5M |
| Net Profit | $147.5M | $135.1M |
| Gross Margin | 44.5% | — |
| Operating Margin | 20.3% | 21.6% |
| Net Margin | 14.3% | 19.1% |
| Revenue YoY | 9.3% | 32.0% |
| Net Profit YoY | 2.4% | 15.5% |
| EPS (diluted) | $1.70 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $708.5M | ||
| Q3 25 | $1.1B | $659.9M | ||
| Q2 25 | $1.0B | $603.3M | ||
| Q1 25 | $941.9M | $558.6M | ||
| Q4 24 | $945.6M | $536.6M | ||
| Q3 24 | $967.1M | $533.3M | ||
| Q2 24 | $965.6M | $528.1M | ||
| Q1 24 | $893.9M | $511.0M |
| Q4 25 | $147.5M | $135.1M | ||
| Q3 25 | $188.4M | $111.1M | ||
| Q2 25 | $159.7M | $90.3M | ||
| Q1 25 | $148.2M | $114.6M | ||
| Q4 24 | $144.1M | $117.0M | ||
| Q3 24 | $174.2M | $96.4M | ||
| Q2 24 | $155.4M | $88.4M | ||
| Q1 24 | $123.8M | $102.6M |
| Q4 25 | 44.5% | — | ||
| Q3 25 | 45.8% | — | ||
| Q2 25 | 45.6% | — | ||
| Q1 25 | 44.9% | — | ||
| Q4 24 | 44.1% | — | ||
| Q3 24 | 44.7% | — | ||
| Q2 24 | 44.4% | — | ||
| Q1 24 | 43.8% | — |
| Q4 25 | 20.3% | 21.6% | ||
| Q3 25 | 21.8% | 21.5% | ||
| Q2 25 | 21.5% | 20.9% | ||
| Q1 25 | 20.9% | 20.3% | ||
| Q4 24 | 19.5% | 23.4% | ||
| Q3 24 | 22.2% | 21.1% | ||
| Q2 24 | 21.6% | 19.9% | ||
| Q1 24 | 19.3% | 20.4% |
| Q4 25 | 14.3% | 19.1% | ||
| Q3 25 | 17.6% | 16.8% | ||
| Q2 25 | 15.6% | 15.0% | ||
| Q1 25 | 15.7% | 20.5% | ||
| Q4 24 | 15.2% | 21.8% | ||
| Q3 24 | 18.0% | 18.1% | ||
| Q2 24 | 16.1% | 16.7% | ||
| Q1 24 | 13.8% | 20.1% |
| Q4 25 | $1.70 | $4.65 | ||
| Q3 25 | $2.18 | $3.86 | ||
| Q2 25 | $1.85 | $3.10 | ||
| Q1 25 | $1.71 | $3.67 | ||
| Q4 24 | $1.65 | $3.67 | ||
| Q3 24 | $1.99 | $3.01 | ||
| Q2 24 | $1.77 | $2.75 | ||
| Q1 24 | $1.41 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $356.2M | $497.0M |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | $2.1B | $459.1M |
| Total Assets | $5.2B | $2.0B |
| Debt / EquityLower = less leverage | 0.96× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $356.2M | $497.0M | ||
| Q3 25 | $302.7M | $285.4M | ||
| Q2 25 | $656.8M | $46.3M | ||
| Q1 25 | $494.5M | $441.4M | ||
| Q4 24 | $503.8M | $669.4M | ||
| Q3 24 | $878.9M | $656.9M | ||
| Q2 24 | $747.5M | $510.9M | ||
| Q1 24 | $391.8M | $407.0M |
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | $2.1B | $459.1M | ||
| Q3 25 | $1.9B | $293.6M | ||
| Q2 25 | $1.8B | $172.4M | ||
| Q1 25 | $1.6B | $593.6M | ||
| Q4 24 | $1.5B | $825.5M | ||
| Q3 24 | $1.6B | $881.4M | ||
| Q2 24 | $1.4B | $763.6M | ||
| Q1 24 | $1.4B | $671.5M |
| Q4 25 | $5.2B | $2.0B | ||
| Q3 25 | $5.2B | $1.8B | ||
| Q2 25 | $4.9B | $1.6B | ||
| Q1 25 | $4.6B | $1.9B | ||
| Q4 24 | $4.5B | $2.1B | ||
| Q3 24 | $5.0B | $2.1B | ||
| Q2 24 | $4.8B | $1.9B | ||
| Q1 24 | $4.3B | $1.8B |
| Q4 25 | 0.96× | — | ||
| Q3 25 | 1.07× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | 1.53× | — | ||
| Q2 24 | 1.69× | — | ||
| Q1 24 | 1.49× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $240.1M | $192.7M |
| Free Cash FlowOCF − Capex | $200.5M | $188.1M |
| FCF MarginFCF / Revenue | 19.4% | 26.6% |
| Capex IntensityCapex / Revenue | 3.8% | 0.6% |
| Cash ConversionOCF / Net Profit | 1.63× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $685.7M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $240.1M | $192.7M | ||
| Q3 25 | $229.5M | $246.2M | ||
| Q2 25 | $209.7M | $148.5M | ||
| Q1 25 | $104.5M | $125.8M | ||
| Q4 24 | $219.0M | $190.7M | ||
| Q3 24 | $231.9M | $149.1M | ||
| Q2 24 | $173.0M | $116.4M | ||
| Q1 24 | $51.1M | $152.7M |
| Q4 25 | $200.5M | $188.1M | ||
| Q3 25 | $209.8M | $235.5M | ||
| Q2 25 | $192.0M | $142.4M | ||
| Q1 25 | $83.4M | $115.8M | ||
| Q4 24 | $194.9M | $183.0M | ||
| Q3 24 | $212.0M | $138.5M | ||
| Q2 24 | $152.1M | $103.5M | ||
| Q1 24 | $23.9M | $147.2M |
| Q4 25 | 19.4% | 26.6% | ||
| Q3 25 | 19.6% | 35.7% | ||
| Q2 25 | 18.8% | 23.6% | ||
| Q1 25 | 8.9% | 20.7% | ||
| Q4 24 | 20.6% | 34.1% | ||
| Q3 24 | 21.9% | 26.0% | ||
| Q2 24 | 15.8% | 19.6% | ||
| Q1 24 | 2.7% | 28.8% |
| Q4 25 | 3.8% | 0.6% | ||
| Q3 25 | 1.8% | 1.6% | ||
| Q2 25 | 1.7% | 1.0% | ||
| Q1 25 | 2.2% | 1.8% | ||
| Q4 24 | 2.5% | 1.4% | ||
| Q3 24 | 2.1% | 2.0% | ||
| Q2 24 | 2.2% | 2.4% | ||
| Q1 24 | 3.0% | 1.1% |
| Q4 25 | 1.63× | 1.43× | ||
| Q3 25 | 1.22× | 2.22× | ||
| Q2 25 | 1.31× | 1.65× | ||
| Q1 25 | 0.71× | 1.10× | ||
| Q4 24 | 1.52× | 1.63× | ||
| Q3 24 | 1.33× | 1.55× | ||
| Q2 24 | 1.11× | 1.32× | ||
| Q1 24 | 0.41× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALLE
| Products | $750.2M | 73% |
| Allegion International | $237.7M | 23% |
| Services | $45.2M | 4% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
